Pfizer reached a number of cooperation within two days to further promote the development of anti-cancer drugs

 On January 10-11, 2022, Pfizer announced a number of important cooperation within two days.
Through the cooperation, Pfizer introduced a number of technologies to supplement its product pipeline, such as further expanding its tumor product pipeline and using AI technology to promote the development of anti-cancer drugs and other drugs.

.
On January 11, PostEra, a biotechnology company focusing on machine learning in the field of preclinical drug development, announced that it has expanded its existing strategic cooperation with Pfizer
.
The expanded multi-objective research program will establish an AI lab where PostEra and Pfizer will jointly advance multiple drug discovery programs
.
AI Lab will design novel machine learning algorithms for medicinal chemistry based on data provided by Pfizer and PostEra's expertise
.
Under the terms of the partnership agreement, PostEra will receive an upfront payment of $13 million and is eligible to receive additional milestone payments totaling up to $248 million, as well as royalties on future products
.
The AI ​​Lab's vision is to combine Pfizer's expertise and data with PostEra's technology to advance drug discovery programs, while also producing an integrated advanced platform that can be deployed in preclinical drug discovery efforts within Pfizer
.
On the same day, Dren Bio announced a partnership with Pfizer
.
It is reported that the cooperation between Pfizer and Dren Bio will focus on the development of bispecific antibodies
.
This bispecific antibody connects tumor cells to myeloid cells, resulting in potent and safe immune stimulation, targeted phagocytosis and cross-presentation of tumor neoantigens, potentially promoting durable clinical responses
.
Under the terms of the agreement, Pfizer will pay Dren Bio an upfront payment of $25 million, Dren Bio is also eligible to receive future development, regulatory and commercial milestone payments totaling more than $1 billion, as well as tiered royalties on future net product sales
.
On January 10, Pfizer announced on its website that the company has entered into an exclusive four-year research collaboration with Beam Therapeutics (hereinafter referred to as "Beam"), focusing on rare genetic diseases of the liver, muscle and central nervous system.
In vivo base editing project
.
Mikael Dolsten, Chief Scientific Officer of Pfizer, said, "We see our collaboration with Beam as an opportunity to advance the next generation of gene editing therapies, an exciting frontier of science with the opportunity to help patients with rare genes be cured
.
" The company is focused on developing a new class of targeted drugs using "lipid nanoparticle" (LNP) base editing technology that targets only a single base in the genome and does not cause double-strand breaks in DNA
.
Compared with traditional gene editing methods, this method is more precise, more efficient, and reduces the potential risks of gene editing
.
Under the agreement, Beam will receive an initial $300 million upfront payment and is eligible to receive up to $1.
05 billion in milestone payments in the future, for a total potential collaborative project cost of up to $1.
35 billion
.
In addition, on January 10, Pfizer also announced a development and option agreement with Acuitas Therapeutics, whereby Pfizer will have the option to acquire Acuitas' LNP technology on a non-exclusive basis for vaccines or therapeutic products with up to 10 targets.
development
.